Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

FDA Releases CRLs for Previous Drug and Biologic Product Applications

July 10th 2025

The FDA has published a collection of complete response letters that were seeking the approval of drugs or biologic products between 2020 and 2024.

Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Long-Term Efficacy in Untreated CLL/SLL

July 9th 2025

Fixed-duration ibrutinib plus venetoclax was effective with nearly 70 months of follow-up in patients with untreated CLL/SLL.

Expert Investigators Highlight Cross-Cancer Updates for Fellows From the 2025 AACR Annual Meeting

July 1st 2025

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Dr Halmos on Differentiating Neuroendocrine Tumors From Neuroendocrine Carcinomas

June 27th 2025

Balazs Halmos, MD, discusses the differences in presentation and available treatments between neuroendocrine tumors and neuroendocrine carcinomas.

Obrixtamig Leverages DLL3 Targeting to Offer a Potential Treatment Option in Extrapulmonary Neuroendocrine Carcinoma

June 27th 2025

Balazs Halmos, MD, discusses the DLL3-targeted BiTE obrixtamig for the treatment of patients with extrapulmonary neuroendocrine carcinoma.

Quizartinib Plus Chemotherapy Shows Strong Activity in FLT3-ITD–Positive, NPM1-Mutated AML

June 26th 2025

FLT3-ITD positivity plus mutations in NPM1 and epigenetic regulatory genes led to heightened efficacy of quizartinib plus chemotherapy in newly diagnosed AML.

NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC

June 25th 2025

The NCCN Clinical Practice Guidelines in Oncology for NSCLC recommend taletrectinib for the treatment of patients with advanced ROS1-positive NSCLC.

FDA Grants Priority Review to Revumenib for Relapsed/Refractory NPM1-Mutant AML

June 25th 2025

Revumenib’s sNDA has received priority review from the FDA for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia.

Additional Treatment Options Underscore the Need for Collaboration and Mutational Testing in GIST

June 24th 2025

Robin Jones MD, MBBS, MRCP, discusses the treatment landscape of GIST and how patients can be effectively treated in the community.

Real-World Data Help to Inform Treatment Selection in Metastatic Urothelial Carcinoma

June 23rd 2025

Amit Mehta, MD, discusses the landscape of metastatic urothelial carcinoma, including data updates as well as treatment selection and safety considerations.

Oncology Fellowship Often Fails to Include Training in Gender Equity Issues

June 23rd 2025

Ana Velázquez Mañana, MD, MSc, discusses survey findings that revealed gender equity training for oncology fellows is often lacking.

UM171 Cell Therapy Earns Positive CHMP Opinion for Hematological Malignancies

June 20th 2025

The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.

Nirogacestat Awaits Review Following Positive CHMP Opinion for Desmoid Tumors

June 20th 2025

The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.

CHMP Recommends EU Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

June 20th 2025

The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

June 19th 2025

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

Dr Jones on the Evolving Treatment Landscape in GIST

June 19th 2025

Robin Jones, MD, MRCP, discusses the treatment armamentarium for patients with gastrointestinal stromal tumors.

Updated Data From Phase 1 Trials Support Shifts in the Lung Cancer Treatment Paradigm

June 19th 2025

Martin E. Gutierrez, MD, discusses steps towards a continuous shift in both the NSCLC and SCLC treatment paradigms, based on trials presented at ASCO 2025.

Choosing Clinical End Points in China for US Bridging Studies

June 19th 2025

Evan S. Wu, MD, PhD, delves into the one of the most pivotal aspects of designing a successful bridging study: the selection of clinical end points.

Telisotuzumab Vedotin Maintains Efficacy Across Key Subgroups in Pretreated NSCLC With c-MET Overexpression

June 19th 2025

Joshua K. Sabari, MD, discusses the role of telisotuzumab vedotin in patients with locally advanced/metastatic NSCLC with c-MET overexpression.

Dr Chung on the Potential Role for Ficerafusp Alfa Plus Pembrolizumab in the HPV-Negative HNSCC Paradigm

June 18th 2025

Christine Chung, MD, contextualizes efficacy data with ficerafusp alfa plus pembrolizumab within the larger treatment paradigm for HPV-negative HNSCC.